medigraphic.com
ISSN 1684-1824 (Electronic)

2022, Number 2

<< Back Next >>

Rev Méd Electrón 2022; 44 (2)

Efficacy of computed tomography in the follow-up to lung cancer treated with Cuban immunotherapy

Camacho-Sosa K, Martí-Coruña MC, Ferreira-Moreno VG, García-Soto J Alonso LL, Rolando, Carreño RIE

Language: Spanish
References: 19
Page: 278-287
PDF size: 847.95 Kb.


ABSTRACT

Introduction: lung cancer represents the first cause of oncological death in the world. Computed tomography is the most used diagnostic mean to classify the disease by stages.
Objective: to determine the efficacy of computed tomography in the evaluation of the disease pseudo-progression in patients with non-small cells lung cancer, treated with Cuban immunotherapy.
Materials and methods: a longitudinal, retrospective, analytical study was conducted in patients with non-small cells lung cancer in advanced stage, treated with Cuban active immunotherapy after the first line of treatment with chemotherapy and chemoradiotherapy, between January 1, 2013 and December 31, 2017. The universe were 91 patients treated with Racotumomab and CIMAvax-EGF. Data were collected from personal clinical records, incorporated in an Excel database and statistically analyzed with the SPSS 23 package.
Results: 28 patients from the total received the Racotumomab vaccine and 63 received the CIMAvax-ECG vaccine. 12.5 % of those treated with Racotumomab and 28 % of those treated with CIMAvax-ECG pseudo progressed. The greatest survival was found in pseudo progressors.
Conclusions: the computed tomographic studio is efficacious in evaluating the response of the disease pseudo progression in patients with non-small cells lung cancer, treated with Cuban immunotherapy.


REFERENCES

  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet]. 2018 [citado 20/11/2020];68:394-424. Disponible en: Disponible en: https://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.3322/caac.21492 1.

  2. Ministerio de Salud Pública. Dirección Nacional de Estadísticas. Anuario Estadístico de Salud 2019 [Internet]. La Habana: MINSAP; 2020 [citado 20/11/2020]. Disponible en: Disponible en: https://files.sld.cu/bvscuba/files/2020/05/Anuario-Electr%c3%b3nico-Espa%c3%b1ol-2019-ed-2020.pdf 2.

  3. López-Ríos F, De Castro J, Concha A, et al. Actualización de las recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón avanzado de célula no pequeña. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica. Rev Esp Patol [Internet]. 2015 [citado 26/12/2018];48(2):80-9. Disponible en: Disponible en: https://www.elsevier.es/es-revista-revista-espanola-patologia-297-articulo-actualizacion-recomendaciones-determinacion-biomarcadores-el-S1699885514001159 3.

  4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. Citado en PubMed; PMID: 30620402.

  5. ESMO2019. Cáncer de pulmón. Impower 110: Atezolizumab en CPCNP con alta expresión de PD-L1, septiembre 27, 2019 [Internet]. México: ScienceLink; 2019 [citado 21/12/2020]. Disponible en: Disponible en: https://sciencelink.com/single-noticia.php?id=2592 5.

  6. Planchard D, Popat S, Kerr K, et al. Metastatic non-small Cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(suppl 4):192-237. Citado en PubMed; PMID: 30285222.

  7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer [Internet]. Pennsylvania: NCCN; 2020 [citado 26/06/2021]. Disponible en: Disponible en: https://www2.tri-kobe.org/nccn/guideline/lung/english/non_small.pdf 7.

  8. Camacho Sosa K, Santiesteban Álvarez E, Herrera Suárez A, et al. Ensayos clínicos en pacientes con cáncer de pulmón en Matanzas. 2019. Rev Méd Electrón [Internet]. 2019 [citado 20/11/2020];41(5). Disponible en: Disponible en: http://www.revmedicaelectronica.sld.cu/index.php/rme/article/view/3383/4586 8.

  9. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39-51. Citado en PubMed; PMID: 26762738.

  10. DeVita VT Jr, Lawrence TS, Rosenberg SA. Cancer: Principles and Practice of Oncology. . 11th ed. [Internet] Philadelphia: Lippincott Williams & Wilkins; 2019 [citado 20/11/2020]. Disponible en: Disponible en: https://www.wolterskluwer.com/en/know/cancer-principles-and-practice-of-oncology 10.

  11. Flores López A, Morán Martínez J, Martínez Arroyo S, et al. Criterios de evaluación en tumores sólidos (RECIST 1.1) en pacientes con cáncer primario y/o metastásico o enfermedad metastásica recurrente. Rev SCientifica [Internet]. 2018 [citado 20/11/2020];16(1):8-12. Disponible en: Disponible en: http://www.investigacionyposgrado.uadec.mx/site/wp-content/uploads/2020/07/2018-Criterios-de-Evaluación-en-Tumores-Sólidos-1.1-RECIST-1.1-en-pacientes-con-Cáncer-Primario-yo-Metastásico-o-Enfermedad-Metastásica-Recurrente.pdf 11.

  12. Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing im-munotherapeutics. Lancet Oncol. 2017;18(3):e143-52. Citado en PubMed; PMID: 28271869.

  13. Kim HK, Heo MH, Lee HS, et al. Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. Cancer Chemother Pharmacol. 2017;80(3):591-8. Citado en PubMed; PMID: 28733892.

  14. JP Impresores. Diagnóstico y tratamiento del cáncer de pulmón [Internet]. La Habana: Editorial Ciencias Médicas; 2020 [citado 20/11/2020]. Disponible en: Disponible en: http://www.bvs.sld.cu/libros/programa_integral_cancer_pulmon/programa_cancer_pulmon.pdf 14.

  15. Wang GX, Guo LQ, Gainor JF, et al. Immune checkpoint inhibitors in lung cancer: Imaging Considerations. AJR Am J Roentgenol. 2017;209(3):567-75. Citado en PubMed; PMID: 28657846.

  16. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-20. Citado en PubMed; PMID: 19934295.

  17. Hodi FS, Hwu WJ, Kefford R. Evaluation of immune-related response criteria and RECIST v1·1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol [Internet]. 2016 [citado 20/11/2020];34(13):1510-7. Disponible en: Disponible en: https://doi:10.1200/JCO.2015.64.0391 17.

  18. Hochmair MJ, Schwab S, Burghuber OC, et al. Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy. Lung Cancer [Internet]. 2017 [citado 20/11/2020];113:4-6. Disponible en: Disponible en: https://doi:10.1016/j.lungcan.2017.08.020 18.

  19. Duchnowska R. Pseudoprogression during immunotherapy of cancers. Oncol Clin Pract [Internet]. 2017 [citado 20/11/2020];13(2):57-60. Disponible en: Disponible en: https://doi:10.5603/OCP.2017.0009 19.




2020     |     www.medigraphic.com